Drug
1018 Iss Immunostimulatory Oligonucleotide
1018 Iss Immunostimulatory Oligonucleotide: highest development phase Phase 1, developed by Dynavax Technologies. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Dynavax Technologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| 1018 ISS immunostimulatory oligonucleotide NCT00403052 | Phase 1 | Colorectal Neoplasms |
Latest
No recent events.
Follow 1018 Iss Immunostimulatory Oligonucleotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.